Clinical trials: Pulmonary Tuberculosis
Pulmonary Tuberculosis
Channa Striata and Curcuma Domestica Supplementation in Patients With Active Pulmonary Tuberculosis
This study aims to evaluate the effect of combined supplementation with Channa striata extract and Curcuma domestica rhizome on nutritional status, inflammatory markers, and quality of life in patients with active pulmonary…
- Trial name
- NCT07887724
- Testing
- CHANA STRIATA AND CURCUMA
- Where
- 2 sites in Indonesia
- Volunteers
- 80 people
- Sponsor
- DINA KEUMALA SARI
Pulmonary Tuberculosis
Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
A5409/RAD-TB is an adaptive Phase 2 randomized, controlled, open-label, dose-ranging, platform protocol to evaluate the safety and efficacy of multidrug regimens for the treatment of adults with drug-susceptible pulmonary…
- Trial name
- RAD-TB (NCT06192160)
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- 30 sites in Botswana, Brazil and 12 more
- Volunteers
- 315 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis
Platform Assessing Regimens and Durations In a Global Multisite Consortium for TB
The UNITE4TB consortium is a group of universities and pharmaceutical companies funded by the European Union. This consortium are carrying out a trial to find better and faster ways to treat tuberculosis (TB).
- Trial name
- PARADIGM4TB (NCT06114628)
- Testing
- Ganfeborole, BTZ-043, Bedaquiline (B)
- Where
- 11 sites in Moldova, South Africa and 3 more
- Volunteers
- 2,500 people
- Sponsor
- University College, London
Tuberculosis, Pulmonary, Other Specified Pulmonary Tuberculosis
BTZ-043 Dose Evaluation in Combination and Selection
This is a phase 2B, open label study, that will compare the safety and efficacy of three experimental regimens consisting of bedaquiline and delamanid in combination with different doses of BTZ-043, a novel antibiotic, in adult…
- Trial name
- DECISION (NCT05926466)
- Testing
- BTZ-043, Bedaquiline, Delamanid
- Where
- 4 sites in South Africa, Tanzania
- Volunteers
- 92 people
- Sponsor
- Michael Hoelscher
Tuberculosis, Multidrug-Resistant, Tuberculosis
Linezolid Dosing Strategies in Drug-Resistant TB
The purpose of the study was to evaluate the efficacy (how well the medicines work) and tolerability (whether participants stop treatment because of side effects from a drug) of an anti-TB treatment regimen that compared two…
- Conditions
- Tuberculosis, Multidrug-Resistant, Tuberculosis, Tuberculosis, Pulmonary
- Trial name
- NCT05007821
- Testing
- Linezolid 600 mg, Linezolid 1200 mg (QD), Linezolid 1200 mg (TIW)
- Where
- 13 sites in Botswana, Brazil and 5 more
- Volunteers
- 138 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, Pulmonary
Digital Health Intervention to Improve TPT Uptake
Despite the evidence of the prevention and control measures of tuberculosis (TB), it still has an impact on the health, social, and economic aspects of the population.
- Trial name
- DHiTPT (NCT07313995)
- Testing
- Digital health intervention
- Where
- 14 sites in Ethiopia
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Arba Minch University
Tuberculosis, Pulmonary
Study of Combinations of Novel Promising Drugs for Pulmonary Tuberculosis
A phase 2, two-part, multicentre, open label, controlled, randomised clinical trial in adult participants with newly diagnosed, sputum-positive pulmonary drug-sensitive tuberculosis (DSTB).
- Trial name
- SYNERGY (NCT07773610)
- Testing
- TBAJ-587 50 mg, Pretomanid 200mg, Linezolid 600Mg Tab
- Where
- South Africa
- Volunteers
- 135 people
- Sponsor
- TASK Applied Science
Pneumonia, Tuberculosis, Pulmonary
The LalelaLung Study: Digital Stethoscope Clinical Evaluation
Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries.
- Conditions
- Pneumonia, Tuberculosis, Pulmonary, Respiratory Tract Infections, Bronchiolitis
- Trial name
- LaLeLa (NCT07631377)
- Testing
- StethoMe AI-enabled digital stethoscope system, Standard IMCI assessment
- Volunteers
- 350 people
- Sponsor
- Johns Hopkins University
Tuberculosis, Pulmonary, Tuberculosis Infection
Short-course Regimens for the Treatment of Pulmonary Tuberculosis
The purpose of this study is to determine whether one or two 17-week regimens of tuberculosis treatment bedaquiline (B or BDQ), moxifloxacin (M), pyrazinamide (Z)-- (BMZ) plus either Rifabutin (Rb) or Delamanid (D or DLM) are as…
- Trial name
- CRUSH-TB (NCT05766267)
- Testing
- Rifabutin, Delamanid, Bedaquiline
- Where
- 8 sites in United States, Canada and 4 more
- Volunteers
- 288 people
- Sponsor
- Centers for Disease Control and Prevention
Tuberculosis, Pulmonary
Fibroblast Activating Protein (FAP) PET/CT in Adults With Tuberculosis
This is an early phase study in patients with Tuberculosis (TB) to evaluate Fibroblast Activating Protein (FAP) activation as a marker of fibrosis.
- Trial name
- NCT07830771
- Testing
- [18F]-FAPI-74
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Pennsylvania
Tuberculosis, Pulmonary
Four Months Moxifloxacin Containing Daily Regimen Study Among New Pulmonary Tuberculosis Patients
The 4-month daily regimen containing moxifloxacin (2HRZEM 7 / 2HRM7) of ICMR-NIRT was studied in 321 sputum positive pulmonary TB patients in a randomised clinical trial.
- Trial name
- NCT05047055
- Testing
- Isoniazid, Rifampicin, Pyrazinamide
- Where
- India
- Volunteers
- 550 people
- Sponsor
- Tuberculosis Research Centre, India
Lung Cancer, Tuberculosis (TB)
Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance With Follow-up Tests After Abnormal Chest X-ray Findings Interpret by Artificial Intelligent
The study titled "Effectiveness of Chat-based Mobile Application for Consultation (Zalo) in Improving Compliance with Follow-up Tests after Abnormal Chest X-ray Findings Interpreted by Artificial Intelligence" aims to evaluate…
- Conditions
- Lung Cancer, Tuberculosis (TB), Chat-based Mobile Application, Compliance Behavior
- Trial name
- NCT07234929
- Testing
- chat-based mobile application (Zalo)
- Where
- Vietnam
- Volunteers
- 2,692 people, healthy volunteers welcome
- Sponsor
- Gia Dinh People Hospital
Post Tuberculosis, Lung Disease
TB Type and Spirometry Result vs. Functional Capacity Based on 6MWT in People With Post-TB Lung Disease
Post-Tuberculosis Lung Disease (PTLD) is defined as chronic respiratory impairment due to previous pulmonary TB. Children recovering from pulmonary TB undergo ongoing respiratory health challenges, including more frequent…
- Conditions
- Post Tuberculosis, Lung Disease, Functional Capacity, Spirometry
- Trial name
- NCT07451899
- Where
- Indonesia
- Volunteers
- 23 people
- Sponsor
- Universitas Padjadjaran
TB - Tuberculosis, PTLD
Intergrated Service Delivery for Lung Health Conditions
The Advancing Lung Health in Zambia project aims to improve access to integrated screening, diagnosis, and management of tuberculosis (TB) and other priority respiratory diseases at community and primary healthcare levels.
- Conditions
- TB - Tuberculosis, PTLD, COPD (Chronic Obstructive Pulmonary Disease), Computer Aided Diagnosis
- Trial name
- TB REACH W11 (NCT07816523)
- Testing
- Intergrated lung health screening, AI-Enabled Cough Sound Screening for Tuberculosis, Post-TB Lung Disease evaluation
- Where
- Zambia
- Volunteers
- 20,300 people, healthy volunteers welcome
- Sponsor
- Centre for Infectious Disease Research in Zambia
Tuberculosis, Inflammation Biomarkers
Effects of Adjunct Omega-3 Long Chain Polyunsaturated Fatty Acids in Pulmonary Tuberculosis Patient: an Early Bactericidal Activity and Inflammatory Trial
The goal of this randomized controlled trial is to evaluate the early bactericidal activity, early inflammatory response, and safety of omega-3 long chain polyunsaturated fatty acid (n-3 PUFA) supplementation in adult patients…
- Conditions
- Tuberculosis, Inflammation Biomarkers, Liver Function Tests, Iron Status
- Trial name
- TREAT 3 (NCT07118059)
- Testing
- Omega-3 (EPA+DHA)
- Where
- South Africa
- Volunteers
- 40 people
- Sponsor
- North-West University, South Africa
Multidrug-Resistant Tuberculosis, Isoniazid Resistant Pulmonary Tuberculosis
Line Probe Assay Evaluation Study
This is a multi-center, blinded study to determine the performance of the YD Diagnostic Corporation (YD) REBA MTB-MDR® and Hain Genotype MTBDRplus V2 kit in a total of 600 clinical isolates and 900 residual sputum samples from…
- Conditions
- Multidrug-Resistant Tuberculosis, Isoniazid Resistant Pulmonary Tuberculosis, Rifampicin Resistant Tuberculosis, Pulmonary Tuberculoses
- Trial name
- YD (NCT02984579)
- Testing
- YD REBA MTB-MDR, Hain Genotype MTBDRplus V1, Hain Genotype MTBDRplus V2
- Volunteers
- 888 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
PRISM-TB is an international, seamless, multicenter, open-label, randomized, controlled, pragmatic, stratified medicine, treatment shortening, multi-arm multi-stage (MAMS), noninferiority Phase 2/3 clinical trial for…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR
- Trial name
- PRISM-TB (NCT06441006)
- Testing
- Bedaquiline, Linezolid, Pretomanid
- Where
- 6 sites in Mongolia, Pakistan and 3 more
- Volunteers
- 400 people
- Sponsor
- University of California, San Francisco
Pulmonary Tuberculoses, Other Specified Pulmonary Tuberculosis
BTZ-043 - Multiple Ascending Dose (MAD) to Evaluate Safety, Tolerability and Early Bactericidal Activity (EBA)
This is a prospective, open label, two-centre, randomized, controlled, two-stage, phase Ib/IIa study to evaluate the safety, tolerability, PK, drug-drug interaction and bactericidal activity of BTZ-043 administered orally once…
- Trial name
- NCT04044001
- Testing
- BTZ-043, Rifafour e-275®, Probe Drug Cocktail
- Where
- 2 sites in South Africa
- Volunteers
- 78 people
- Sponsor
- Michael Hoelscher
Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
To evaluate the efficacy, safety and tolerability at 8 weeks (2-months), 52 weeks (12-months), and 104 Weeks (24-months) post the start of the following treatment regimens in participants with: Drug Sensitive TB (DS-TB) patients…
- Conditions
- Tuberculosis, Pulmonary, Tuberculosis, Multidrug-Resistant, Tuberculosis, MDR, Tuberculosis
- Trial name
- NCT03338621
- Testing
- Pretomanid, Bedaquiline, Moxifloxacin
- Where
- 26 sites in Brazil, Georgia and 6 more
- Volunteers
- 455 people
- Sponsor
- Global Alliance for TB Drug Development
Tuberculosis, Lung Diseases
Alternative Diagnoses in Patients About to Start Empiric Tuberculosis Treatment
This study is being conducted to determine whether in patients who are diagnosed with tuberculosis on a clinical basis (where tuberculosis is not found in the sputum) might have other lung diseases than tuberculosis.
- Trial name
- ALTTB (NCT06737029)
- Testing
- Enhanced diagnostic workup
- Where
- Zambia
- Volunteers
- 311 people
- Sponsor
- Stichting Longartsen voor Afrika